We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
23 May 2018
On April 28 2018 the Office of the United States Trade Representative (USTR) issued its Special 301 Report, which is the result of:
"an annual review of the state of IP protection and enforcement in U.S. trading partners around the world, which the Office of the United States Trade Representative (USTR) conducts pursuant to Section 182 of the Trade Act of 1974, as amended by the Omnibus Trade and Competitiveness Act of 1988, the Uruguay Round Agreements Act, and the Trade Facilitation and Trade Enforcement Act of 2015 (19 U.S.C. § 2242)."(1)
Section I.A.1 of the report concerns pharmaceutical and medical device innovation and market access and:
Whereas Mexico has a relatively strong IP protection system for pharmaceutical products (which includes broad criteria on patentable subject matter, linkage between patents and marketing authorisations and limited regulatory data exclusivity), market access has been the subject of continuous public policy debate and adjustment.
In Mexico, several institutions provide public health services (the main ones being the Mexican Social Security Institute, the Institute for Social Security and Services for State Workers and Seguro Popular). Pharmaceutical products and devices are acquired predominantly through direct purchase through tendering processes, but complex listing must occur before a product can be tendered.
For further information on this topic please contact Juan Luis Serrano-Leets at Sanchez-DeVanny Eseverri SC by telephone (+52 55 5029 8500) or email (firstname.lastname@example.org). The Sanchez-DeVanny Eseverri SC website can be accessed at www.sanchezdevanny.com.
(1) Special 301 Report, page 2.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.